{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968870",
  "id": "02968870",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0834",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrqtxw4h73d0.pdf",
  "summary": "### Clinical Trial Update Summary:  \n- **Phase 1b Trial Results**:  \n  - **Response Rates**: 75% ORR (9/12 patients; 6 Complete Responses, 3 Partial Responses) in relapsed/refractory DLBCL.  \n  - **Durability**: First patient cancer-free at 15+ months; others with durable responses at 2, 5, and 11+ months.  \n  - **Patient Profile**: Heavily pre-treated (failed 3\u20136 prior therapies, including autologous CAR-T).  \n\n- **Regulatory/Commercial Milestones**:  \n  - **FDA Fast Track Designation**: Granted March 2025 for DLBCL.  \n  - **Next Steps**: Type B (End of Phase 1) meeting with FDA in Q4 2025 to discuss pivotal trial design.  \n\n- **Trial Expansion**: Now enrolling CAR T-na\u00efve patients in niche indications (e.g., PCNSL, CLL/SLL, MZL, WM, FL).  \n\n- **Upcoming Catalyst**: Additional data update expected in coming months.  \n\n**No capital markets or liquidity-impacting information disclosed.**",
  "usage": {
    "prompt_tokens": 2759,
    "completion_tokens": 243,
    "total_tokens": 3002,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:00:55.288097"
}